## Irene Bultink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5000955/publications.pdf

Version: 2024-02-01

218677 233421 2,084 51 26 45 h-index citations g-index papers 54 54 54 2994 times ranked docs citations citing authors all docs

#	Article	IF	Citations
1	Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 2044-2050.	6.7	212
2	Sensing of latent EBV infection through exosomal transfer of $5\hat{a} \in ^2$ pppRNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E587-96.	7.1	136
3	Advances in Glucocorticoid-Induced Osteoporosis. Current Rheumatology Reports, 2011, 13, 233-240.	4.7	135
4	Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology, 2017, 56, 121-128.	1.9	122
5	Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care and Research, 2012, 64, 2-8.	3.4	99
6	Inflammatory Rheumatic Disorders and Bone. Current Rheumatology Reports, 2012, 14, 224-230.	4.7	86
7	Optimizing fracture prevention: the fracture liaison service, an observational study. Osteoporosis International, 2014, 25, 701-709.	3.1	73
8	Longâ€Term Clinical Outcomes in a Cohort of Adults With Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 290-301.	5.6	69
9	Osteoarthritis and Osteoporosis: What Is the Overlap?. Current Rheumatology Reports, 2013, 15, 328.	4.7	67
10	Management of osteoporosis in rheumatoid arthritis patients. Expert Opinion on Pharmacotherapy, 2015, 16, 559-571.	1.8	64
11	Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporosis International, 2013, 24, 1827-1833.	3.1	63
12	Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology, 2016, 55, 939-948.	1.9	62
13	Glucocorticoids, Inflammation and Bone. Calcified Tissue International, 2018, 102, 592-606.	3.1	59
14	Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporosis International, 2014, 25, 1275-1283.	3.1	51
15	Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Science and Medicine, 2016, 3, e000163.	2.7	51
16	Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus <i>vs</i> matched controls. Rheumatology, 2021, 60, 207-216.	1.9	51
17	Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy, 2013, 14, 185-197.	1.8	46
18	Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 389-390.	0.9	41

#	Article	IF	Citations
19	Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Arthritis Research and Therapy, 2006, 8, R183.	3.5	39
20	Bone Disease in Connective TissueÂDisease/Systemic Lupus Erythematosus. Calcified Tissue International, 2018, 102, 575-591.	3.1	39
21	Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2008, 26, 32-8.	0.8	39
22	Lupus and fractures. Current Opinion in Rheumatology, 2016, 28, 426-432.	4.3	38
23	Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis. Drugs, 2019, 79, 1065-1087.	10.9	37
24	The relationship between remission and health-related quality of life in a cohort of SLE patients. Rheumatology, 2019, 58, 628-635.	1.9	36
25	High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. Journal of Rheumatology, 2008, 35, 1053-7.	2.0	34
26	Physiological evidence for diversification of IFN $\hat{1}$ ±- and IFN $\hat{1}$ 2-mediated response programs in different autoimmune diseases. Arthritis Research and Therapy, 2016, 18, 49.	3.5	32
27	Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. Scandinavian Journal of Immunology, 2016, 84, 100-109.	2.7	30
28	Anti-Hinge Antibodies Recognize IgG Subclass– and Protease-Restricted Neoepitopes. Journal of Immunology, 2017, 198, 82-93.	0.8	25
29	Systemic lupus erythematosus and fractures. RMD Open, 2015, 1, e000069.	3.8	23
30	Systemic lupus erythematosus: review of synthetic drugs. Expert Opinion on Pharmacotherapy, 2015, 16, 2793-2806.	1.8	20
31	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. Rheumatology, 2017, 56, 1586-1596.	1.9	20
32	Management of glucocorticoid-induced osteoporosis. Aging Clinical and Experimental Research, 2021, 33, 793-804.	2.9	20
33	Making the invisible visible: bioelectrical impedance analysis demonstrates unfavourable body composition in rheumatoid arthritis patients in clinical practice. Scandinavian Journal of Rheumatology, 2014, 43, 273-278.	1.1	19
34	Prevalence of malnutrition and validation of bioelectrical impedance analysis for the assessment of body composition in patients with systemic sclerosis. Rheumatology, 2017, 56, 1008-1012.	1.9	18
35	Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. Rheumatology, 2021, 60, 5134-5141.	1.9	18
36	New developments in systemic lupus erythematosus. Rheumatology, 2021, 60, vi21-vi28.	1.9	16

#	Article	IF	CITATIONS
37	Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study. Journal of Immunology Research, 2017, 2017, 1-9.	2.2	14
38	Low-molecular-weight heparin and aspirin use in relation to pregnancy outcome in women with systemic lupus erythematosus and antiphospholipid syndrome: A cohort study. Hypertension in Pregnancy, 2017, 36, 8-15.	1.1	12
39	Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use. Clinical and Experimental Rheumatology, 2014, 32, 95-100.	0.8	12
40	Performance of vertebral fracture assessment in addition to dual energy X-ray absorptiometry in patients with rheumatoid arthritis. Rheumatology, 2014, 53, 775-776.	1.9	11
41	Comprehensive approach to study complement C4 in systemic lupus erythematosus: Gene polymorphisms, protein levels and functional activity. Molecular Immunology, 2017, 92, 125-131.	2.2	11
42	FSAPâ€mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE. European Journal of Immunology, 2016, 46, 762-771.	2.9	8
43	Effects of Childhood-onset Systemic Lupus Erythematosus on Academic Achievements and Employment in Adult Life. Journal of Rheumatology, 2021, 48, 915-923.	2.0	8
44	Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence. Lupus Science and Medicine, 2021, 8, e000478.	2.7	7
45	Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial. Osteoporosis International, 2021, 32, 1441-1449.	3.1	4
46	Unexpected severe incident vertebral fractures in patients with systemic lupus erythematosus: comment on the article by Zhu etÂal Lupus, 2015, 24, 222-223.	1.6	3
47	Work participation in patients with systematic lupus erythematosus: a systematic review. Rheumatology, 2021, , .	1.9	2
48	The association between FOK-I vitamin D receptor gene polymorphisms and bone mineral density in patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2015, 33, 765.	0.8	2
49	THU0332â€Use and Reasons for Non-Use of Antimalarial Drugs in a Dutch Cohort of Patients with Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2013, 72, A277.3-A278.	0.9	0
50	P177â€Work participation in patients with systematic lupus erythematosus: a scoping review. , 2020, , .		0
51	Work participation and sick leave in women with systemic lupus erythematosus and matched controls during and after pregnancy. Clinical and Experimental Rheumatology, 2020, 38, 571-572.	0.8	0